Dr. Carey on Everolimus in Metastatic Breast Cancer

Lisa A. Carey, MD
Published Online: Friday, April 5, 2013
Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the use of everolimus in the metastatic and adjuvant settings of breast cancer.

Everolimus, an mTOR inhibitor, has demonstrated benefit to women with acquired endocrine resistance. These patients are treated with an aromatase inhibitor, respond briefly, but eventually develop resistance. It has been seen, Carey says, that adding everolimus to any aromatase inhibitor still produces beneficial results with regard to progression-free survival. Everolimus, and targeting the mTOR pathway in general, is a promising arena in metastatic acquired resistance to endocrine therapies.

Future studies will move everolimus into the adjuvant setting and analyze whether it helps to augment the effectiveness of endocrine therapy.

Online CME Activities
Free CME from PER
Evolving Management Strategies for Triple-Negative Breast Cancer
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer
Cancer Summaries and Commentaries™: Update from Vienna: Advances in the Treatment of Gastrointestinal Cancers
Advances in Targeted Therapy: The Emerging Role of PARP Inhibitors in the Treatment of Cancers
More Reading